Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study

Open Access

24 August 2005

journal article
research article
Published by Springer Nature in BMC Infectious Diseases

Vol. 5 (1) , 67
https://doi.org/10.1186/1471-2334-5-67

Abstract

Background: To compare the adverse events after initiation of nevirapine-based ART among HIV-infected patients who did not receive fluconazole (group A), received fluconazole 400 mg/week (group B), and received fluconazole 200 mg/day (group C).Methods: A retrospective cohort study was conducted among HIV-infected patients who began NVP-based ART between December 2003 and September 2004. Patients were followed up for 6 months. Clinical hepatitis, elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (> 3 times from baseline), and skin rashes were studied.Results: There were 686 patients; 225, 392, and 69 patients in group A, B, and C, respectively. Baseline characteristics including age, previous opportunistic infections, use of antituberculous drugs, and baseline aminotransferase levels among the three groups were similar. Group C had a higher proportion of men (p= 0.016). Baseline median (IQR) CD4 cell counts were 85 (21–159), 18 (7–48), and 16 (5–35) cell/mm³in group A, B, and C, respectively (p< 0.001). Of 2/225 (0.9%), 4/392 (1.0%), and 0/69 (0%) patients in group A, B, and C developed clinical hepatitis (p= 0.705). There were no significant difference of elevated AST or ALT among the three groups (p> 0.05). By logistic regression, receiving fluconazole was not predictive of clinical hepatitis, elevated aminotransferase, or skin rashes. At 6 months after initiating NVP, 174 (77.3%) patients in group A, 309 (78.8%) patients in group B, and 58 (84.1%) patients in group C remained on NVP.Conclusion: Initiation of NVP-based ART among Thais with advance HIV disease receiving fluconazole is safe and well-tolerated. nevirapine should not be contraindicated for patients receiving fluconazole for treatment or prophylaxis of cryptococcosis.

Keywords

This publication has 26 references indexed in Scilit:

Severe Hepatotoxicity Associated with Nevirapine Use in HIV‐Infected Subjects
The Journal of Infectious Diseases, 2005
A multicentre, randomized, double‐blind, placebo‐controlled trial of primary cryptococcal meningitis prophylaxis in HIV‐infected patients with severe immune deficiency
HIV Medicine, 2004
Developing a Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Therapeutic Research Agenda for Resource‐Limited Countries: A Consensus Statement
Clinical Infectious Diseases, 2003
Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus*1
Published by Wolters Kluwer Health ,2003
Failure of a Short-Term Prednisone Regimen to Prevent Nevirapine-Associated Rash: A Double-Blind Placebo-Controlled Trial: The GESIDA 09/99 Study
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
Drug-Drug Interactions of Clinical Significance in the Treatment of Patients with Mycobacterium avium Complex Disease
Clinical Pharmacokinetics, 2000
Practice Guidelines for the Management of Cryptococcal Disease
Clinical Infectious Diseases, 2000
Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
New England Journal of Medicine, 1998
Systemic Antifungal Agents
Drug Safety, 1998
Inter‐subject and ethnic differences in paracetamol metabolism.
British Journal of Clinical Pharmacology, 1986